Question: Recently Indian Council of Medical Research (ICMR) launched India’s first large-scale trial for two new vaccines, named IMMUVAC and VPM1002 to fight against:
(c) Japanese Encephalitis
- Indian Council of Medical Research (ICMR) launched India’s first large-scale trial for two new tuberculosis (TB) vaccines named IMMUVAC and VPM1002.
- These vaccines aim to prevent infection (pre-exposure) or prevent primary progression or reactivation of latent TB infection (post-exposure).
- Both vaccines have been manufactured by Indian pharmaceutical companies.
- Immuvac, which is also known as Mycobacterium Indicus Pranii (MIP), has been manufactured by Ahmedabad based Cadila Pharmaceuticals.
- Another vaccine VPM1002 is manufactured by Serum institute of India, located in Pune, Maharashtra.
- It should be known that until now Bacille Calmette-Guerin (BCG) vaccine is widely used in routine Expanded Programme of Immunization (EPI) across the world.
- Need for the new vaccine is being felt since last many years as over a century old BCG vaccine, for this purpose, provides poor protection against pulmonary disease in adolescents and adults.
- Trial of these vaccines is being carried out upon more than 12,000 healthy household contacts of newly diagnosed TB patients from across six states including Delhi, Maharashtra, Odisha and Karnataka.